JP2023515941A5 - - Google Patents
Info
- Publication number
- JP2023515941A5 JP2023515941A5 JP2022550156A JP2022550156A JP2023515941A5 JP 2023515941 A5 JP2023515941 A5 JP 2023515941A5 JP 2022550156 A JP2022550156 A JP 2022550156A JP 2022550156 A JP2022550156 A JP 2022550156A JP 2023515941 A5 JP2023515941 A5 JP 2023515941A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- bispecific antigen
- chain complementarity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982989P | 2020-02-28 | 2020-02-28 | |
| US62/982,989 | 2020-02-28 | ||
| PCT/US2021/020074 WO2021174113A1 (en) | 2020-02-28 | 2021-02-26 | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023515941A JP2023515941A (ja) | 2023-04-17 |
| JP2023515941A5 true JP2023515941A5 (https=) | 2024-03-01 |
| JP7695260B2 JP7695260B2 (ja) | 2025-06-18 |
Family
ID=75108909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550156A Active JP7695260B2 (ja) | 2020-02-28 | 2021-02-26 | Ｈｅｒ２に結合する二重特異性抗原結合分子およびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11958910B2 (https=) |
| EP (1) | EP4110472A1 (https=) |
| JP (1) | JP7695260B2 (https=) |
| KR (1) | KR20220148200A (https=) |
| CN (1) | CN115175737A (https=) |
| AU (1) | AU2021228225A1 (https=) |
| CA (1) | CA3166619A1 (https=) |
| IL (1) | IL295312A (https=) |
| MX (1) | MX2022010599A (https=) |
| WO (1) | WO2021174113A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7590328B2 (ja) * | 2018-12-21 | 2024-11-26 | レゲネロン ファーマシューティカルス，インコーポレーテッド | ツブリシン及びタンパク質－ツブリシンコンジュゲート |
| KR20220148200A (ko) | 2020-02-28 | 2022-11-04 | 리제너론 파마슈티칼스 인코포레이티드 | Her2에 결합하는 이중특이적 항원 결합 분자 및 이의 사용 방법 |
| WO2021262910A2 (en) * | 2020-06-24 | 2021-12-30 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| CN116390771A (zh) * | 2020-07-13 | 2023-07-04 | 瑞泽恩制药公司 | 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途 |
| US20240307551A1 (en) * | 2021-07-05 | 2024-09-19 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Antibody-drug conjugate and application thereof |
| US20250049938A1 (en) * | 2021-12-01 | 2025-02-13 | Shanghai Institute Of Biological Products Co., Ltd. | Antibody-drug conjugate and use thereof |
| CA3241734A1 (en) * | 2022-01-12 | 2023-07-20 | Amy Han | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
| CN119923415A (zh) * | 2022-08-05 | 2025-05-02 | 成都恩沐生物科技有限公司 | 靶向可二聚化肿瘤抗原和免疫刺激性抗原的多特异性抗体 |
| WO2024138000A1 (en) | 2022-12-21 | 2024-06-27 | Regeneron Pharmaceuticals, Inc. | Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof |
| US20250255980A1 (en) * | 2024-02-12 | 2025-08-14 | Mbrace Therapeutics, Inc. | Antibody-Drug Conjugates Against the Glucose-regulating Protein 78 (GRP78) |
| WO2025199666A1 (en) * | 2024-03-25 | 2025-10-02 | Canwell Biotech Limited | Multivalent linkers for high loading antibody-drug conjugates, and compositions and methods thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US585592A (en) | 1897-06-29 | Reversing-valve | ||
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| EP2167963B1 (en) | 2007-05-23 | 2019-04-17 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
| AU2009275358C1 (en) | 2008-07-21 | 2015-09-24 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| AU2010283632B2 (en) | 2009-08-10 | 2016-08-25 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
| SI2528625T1 (sl) | 2010-04-15 | 2013-11-29 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| EA201390575A1 (ru) | 2010-10-29 | 2014-01-30 | Иммьюноджен, Инк. | Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты |
| CN110078789A (zh) | 2011-05-27 | 2019-08-02 | Ambrx 公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CN103997893B (zh) | 2011-10-14 | 2019-04-12 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
| EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
| BR112014009070B1 (pt) | 2011-10-14 | 2021-11-23 | Medimmune Limited | Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| RU2014124984A (ru) | 2011-12-05 | 2016-01-27 | Идженика Биотерапьютикс, Инк. | Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы |
| CN105142672B (zh) | 2012-10-23 | 2019-04-05 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
| DK2934582T3 (da) | 2012-12-21 | 2020-02-24 | Ichnos Sciences SA | Anti-her2-antistofformulering |
| JP6847388B2 (ja) | 2013-03-15 | 2021-03-31 | レゲネロン ファーマシューティカルス，インコーポレーテッド | 生物活性分子、そのコンジュゲート、及び治療用途 |
| BR112016004023A2 (pt) | 2013-08-26 | 2022-11-16 | Regeneron Pharma | Composição, métodos para preparar uma composição e para tratar uma doença, e, composto |
| EP3083696B1 (en) | 2013-12-20 | 2018-02-14 | F.Hoffmann-La Roche Ag | Bispecific her2 antibodies and methods of use |
| SG11201608192SA (en) | 2014-04-11 | 2016-10-28 | Medimmune Llc | Bispecific her2 antibodies |
| BR112017020149A8 (pt) | 2015-03-27 | 2023-05-02 | Regeneron Pharma | Derivados de maitansinoide, conjugados dos mesmos e métodos de uso |
| CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
| BR112018014759B1 (pt) | 2016-01-25 | 2024-02-27 | Regeneron Pharmaceuticals, Inc | Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso |
| WO2018044540A1 (en) | 2016-08-31 | 2018-03-08 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for detecting protein trafficking |
| ES3046537T3 (en) | 2016-11-08 | 2025-12-02 | Regeneron Pharma | Steroids and protein-conjugates thereof |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| IL269656B2 (en) | 2017-03-31 | 2024-06-01 | Merus Nv | Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene |
| US20200291130A1 (en) | 2017-03-31 | 2020-09-17 | Merus N.V. | Antibodies for the treatment of erbb-2/erbb-3 positive tumors |
| KR102871690B1 (ko) * | 2018-04-30 | 2025-10-16 | 리제너론 파마슈티칼스 인코포레이티드 | Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도 |
| KR20220148200A (ko) | 2020-02-28 | 2022-11-04 | 리제너론 파마슈티칼스 인코포레이티드 | Her2에 결합하는 이중특이적 항원 결합 분자 및 이의 사용 방법 |
-
2021
- 2021-02-26 KR KR1020227031324A patent/KR20220148200A/ko active Pending
- 2021-02-26 EP EP21713314.9A patent/EP4110472A1/en active Pending
- 2021-02-26 AU AU2021228225A patent/AU2021228225A1/en active Pending
- 2021-02-26 IL IL295312A patent/IL295312A/en unknown
- 2021-02-26 US US17/187,511 patent/US11958910B2/en active Active
- 2021-02-26 MX MX2022010599A patent/MX2022010599A/es unknown
- 2021-02-26 JP JP2022550156A patent/JP7695260B2/ja active Active
- 2021-02-26 CN CN202180017266.5A patent/CN115175737A/zh active Pending
- 2021-02-26 WO PCT/US2021/020074 patent/WO2021174113A1/en not_active Ceased
- 2021-02-26 CA CA3166619A patent/CA3166619A1/en active Pending
-
2024
- 2024-03-08 US US18/600,481 patent/US12583939B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023515941A5 (https=) | ||
| JP2023547323A5 (https=) | ||
| JP6454269B2 (ja) | Ｃｄ３３抗体及び癌を処置するためのその使用 | |
| JP2024059609A5 (https=) | ||
| WO2020102779A1 (en) | MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF | |
| KR102949500B1 (ko) | 접합을 위한 폴리펩티드 복합체 및 이의 용도 | |
| JP2019536740A5 (https=) | ||
| CN111712520A (zh) | 磷脂酰肌醇聚糖3抗体及其偶联物 | |
| JP2021523100A5 (https=) | ||
| JP7264831B2 (ja) | 抗ｇｌｏｂｏ ｈ抗体を含有する抗体－薬物コンジュゲートおよびその使用 | |
| JP2024544520A5 (https=) | ||
| JP2025038088A5 (https=) | ||
| EP3200822A1 (en) | Binding molecules, especially antibodies, binding to l1cam (cd171) | |
| JP2022523360A5 (https=) | ||
| US20230312742A1 (en) | CD38 antibodies for the treatment of human diseases | |
| JP2024533457A5 (https=) | ||
| JP2024517760A (ja) | 抗５ｔ４抗体及びその使用 | |
| JP2026512687A (ja) | ヒト化ｌ１ｃａｍ抗体－薬物複合体 | |
| TW202432185A (zh) | 配體－細胞毒性藥物綴合物及其藥物用途 | |
| JP2024527235A5 (https=) | ||
| US20240417457A1 (en) | Antibodies directed against alpha-folate receptor | |
| JP2024540536A5 (https=) | ||
| KR20250175021A (ko) | Nectin-2에 특이적으로 결합하는 인간화 항체 및 이의 용도 | |
| WO2025233679A1 (en) | Compositions and methods related to a combination therapy of sting agonists and antibody drug conjugates | |
| CN120829509A (zh) | 抗ror1抗体、其免疫缀合物及其应用 |